Skip to main content
Signal8
Launch Terminal

LEXICON PHARMACEUTICALS, INC. (LXRX)

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRXHealthcare
-4.05%$1.42
AH$1.50+5.63%vs close
Mkt Cap$631.84M
Float226.44M
O/S444.96M
Vol
$ Vol
RVOL
Inst Own82.0%
SI11.8%
Earnings
Dilution
Lexicon Pharmaceuticals, Inc. logoNASDAQ:LXRX$1.42-4.05%
Upcoming Catalysts
Phase Distribution
61 lead-sponsored trials·1 active·55 completed
Phase 126
Phase 1/21
Phase 216
Phase 318
(7 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

    Telotristat etiprate, Placebo-matching telotristat etiprate

    Carcinoid Syndrome

    Enrollment
    135
    Start
    Jan 2013
    Primary Completion
    Mar 2016
    Completion
    Mar 2016
    NCT01677910
  • Phase 3
    Completed

    Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

    Telotristat etiprate

    Carcinoid Syndrome

    Enrollment
    124
    Start
    Jan 2014
    Primary Completion
    Sep 2018
    Completion
    Sep 2018
    NCT02026063
  • Phase 3
    Completed

    Telotristat Etiprate for Carcinoid Syndrome Therapy

    Telotristat etiprate, Placebo

    Carcinoid Syndrome

    Enrollment
    76
    Start
    Mar 2014
    Primary Completion
    Mar 2016
    Completion
    Mar 2016
    NCT02063659
  • Phase 3
    Completed

    Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

    Placebo, Sotagliflozin

    Type 1 Diabetes Mellitus

    Enrollment
    793
    Start
    Mar 2015
    Primary Completion
    Sep 2016
    Completion
    Feb 2017
    NCT02384941
  • Phase 3
    Completed

    Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

    Sotagliflozin, Sotagliflozin

    Type 1 Diabetes Mellitus

    Enrollment
    782
    Start
    May 2015
    Primary Completion
    Nov 2016
    Completion
    Jun 2017
    NCT02421510
  • Phase 3
    Completed

    A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone

    Sotagliflozin, Placebo

    Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood

    Enrollment
    1,405
    Start
    Sep 2015
    Primary Completion
    Apr 2017
    Completion
    Apr 2017
    NCT02531035
  • Phase 3
    Completed

    Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

    Sotagliflozin (SAR439954), Placebo

    Type 2 Diabetes Mellitus

    Enrollment
    399
    Start
    Nov 2016
    Primary Completion
    Apr 2019
    Completion
    May 2019
    NCT02926937
  • Phase 3
    Completed

    Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

    Sotagliflozin (SAR439954), Placebo

    Type 2 Diabetes Mellitus

    Enrollment
    518
    Start
    Nov 2016
    Primary Completion
    Feb 2019
    Completion
    Mar 2019
    NCT02926950
  • Phase 3
    Completed

    Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

    Sotagliflozin (SAR439954), Placebo

    Type 2 Diabetes Mellitus

    Enrollment
    507
    Start
    Feb 2017
    Primary Completion
    Apr 2019
    Completion
    Apr 2019
    NCT03066830
  • Phase 3
    Completed

    A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

    Placebo, Sotagliflozin

    Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4

    Enrollment
    277
    Start
    Aug 2017
    Primary Completion
    May 2019
    Completion
    Dec 2019
    NCT03242018
  • Phase 3
    Completed

    Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

    Placebo, Sotagliflozin

    Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3

    Enrollment
    787
    Start
    Aug 2017
    Primary Completion
    Mar 2019
    Completion
    Oct 2019
    NCT03242252
  • Phase 3
    Completed

    Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

    Sotagliflozin, Insulin glargine (HOE901)

    Type 2 Diabetes Mellitus

    Enrollment
    571
    Start
    Sep 2017
    Primary Completion
    Sep 2019
    Completion
    Sep 2019
    NCT03285594
  • Phase 3
    Terminated

    Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

    Sotagliflozin, Placebo

    Heart Failure, Type 2 Diabetes Mellitus +1

    Enrollment
    10,584
    Start
    Dec 2017
    Primary Completion
    Jul 2020
    Completion
    Jul 2020
    NCT03315143
  • Phase 3
    Completed

    Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

    Sotagliflozin (SAR439954), Glimepiride

    Type 2 Diabetes Mellitus

    Enrollment
    954
    Start
    Dec 2017
    Primary Completion
    Aug 2019
    Completion
    Sep 2019
    NCT03332771
  • Phase 3
    Completed

    Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

    Sotagliflozin, Empagliflozin

    Type 2 Diabetes Mellitus

    Enrollment
    770
    Start
    Nov 2017
    Primary Completion
    May 2019
    Completion
    May 2019
    NCT03351478
  • Phase 3
    Terminated

    Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

    Sotagliflozin, Placebo

    Type 2 Diabetes Mellitus

    Enrollment
    376
    Start
    Feb 2018
    Primary Completion
    May 2019
    Completion
    May 2020
    NCT03386344
  • Phase 3
    Terminated

    Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

    Sotagliflozin, Placebo

    Heart Failure, Type 2 Diabetes Mellitus

    Enrollment
    1,222
    Start
    Jun 2018
    Primary Completion
    Jun 2020
    Completion
    Jun 2020
    NCT03521934
  • Phase 3
    Active, not recruiting

    A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

    Sotagliflozin, Placebo

    Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

    Enrollment
    500
    Start
    Sep 2024
    Primary Completion
    Jan 2027est.
    Completion
    Feb 2027est.
    NCT06481891
  • Phase 2
    Completed

    Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment

    LX6171 High Dose, LX6171 Low Dose

    Age-Related Memory Disorders

    Enrollment
    103
    Start
    Feb 2008
    Primary Completion
    Oct 2008
    Completion
    -
    NCT00691808
  • Phase 2
    Completed

    Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

    LX1031 High Dose, LX1031 Low Dose

    Irritable Bowel Syndrome

    Enrollment
    155
    Start
    Dec 2008
    Primary Completion
    Jul 2009
    Completion
    Aug 2010
    NCT00813098
  • Phase 2
    Completed

    Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

    Telotristat etiprate, Octreotide LAR Depot

    Carcinoid Syndrome

    Enrollment
    23
    Start
    Mar 2009
    Primary Completion
    Jun 2014
    Completion
    Jun 2014
    NCT00853047
  • Phase 2
    Completed

    Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

    LX3305 low dose, LX3305 mid dose

    Rheumatoid Arthritis

    Enrollment
    208
    Start
    Jul 2009
    Primary Completion
    Sep 2010
    Completion
    -
    NCT00903383
  • Phase 2
    Completed

    Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

    LX4211 Low Dose, LX4211 High Dose

    Type 2 Diabetes Mellitus

    Enrollment
    36
    Start
    Aug 2009
    Primary Completion
    Dec 2009
    Completion
    -
    NCT00962065
  • Phase 2
    Completed

    Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

    Telotristat etiprate

    Carcinoid Syndrome

    Enrollment
    15
    Start
    Jun 2010
    Primary Completion
    Feb 2014
    Completion
    Feb 2014
    NCT01104415
  • Phase 2
    Completed

    Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

    75 mg LX4211, 200 mg LX4211

    Type 2 Diabetes Mellitus

    Enrollment
    299
    Start
    Jun 2011
    Primary Completion
    May 2012
    Completion
    May 2012
    NCT01376557

1-25 of 61

Search ClinicalTrials.gov for “Lexicon Pharmaceuticals”